NLRP3 and Hepatic steatosis: In another recent study, administration of a different Nlrp3 inhibitor called IFM-514 via intra-peritoneal injection (100 mg/kg) daily, 5 days/week for 4 weeks to ApoE−/− mice on a MCD diet was also found to reduce hepatic steatosis, inflammation, and fibrosis (7).